Neogenomics Inc (NEO)

$7.88 -0.10 (-1.25%)
Market Cap 1.04B
Revenue (ttm) 727.33M
Net Income (ttm) -108.03M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -14.85%
Debt to Equity Ratio 0.00
Volume 1,440,300
Avg Vol 1,953,472
Day's Range N/A - N/A
Shares Out 129.81M
Stochastic %K 2%
Beta 1.62
Analysts Sell
Price Target $14.81

Company Profile

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the pr...

Industry: Diagnostics & Research
Sector: Healthcare
Phone: 239 768 0600
Fax: 239 690 4237
Address:
9490 NeoGenomics Way, Fort Myers, United States
carminefox
carminefox Mar. 13 at 9:22 PM
$NEO bag holding this patiently. Hoping for that buy out offer!
0 · Reply
Fabiola_T
Fabiola_T Mar. 13 at 1:08 PM
$NEO lower high set
0 · Reply
DriveForShow
DriveForShow Mar. 12 at 5:04 PM
$NEO Did we finally hit a new bottom?
0 · Reply
Kat_Harington
Kat_Harington Mar. 12 at 2:22 PM
$NEO this thing is DUMPING
0 · Reply
BillionerOfKing
BillionerOfKing Mar. 10 at 8:40 PM
$NEO Current Stock Price: $8.55 Contracts to trade: $9.0 NEO Mar 20 2026 Call Entry: $1.10 Exit: $1.69 ROI: 54% Hold ~29 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
Kat_Harington
Kat_Harington Mar. 9 at 2:16 PM
$NEO haven’t seen a green day in months.
1 · Reply
IN0V8
IN0V8 Mar. 6 at 2:33 PM
$NEO Added at $8.95
0 · Reply
IN0V8
IN0V8 Mar. 2 at 5:49 PM
$NEO added at $9.2
0 · Reply
DriveForShow
DriveForShow Mar. 2 at 3:05 PM
$NEO Figured the 200MA would get tested and it’s just about there. Will it hold $9.23?
0 · Reply
GordoHLYK13
GordoHLYK13 Feb. 27 at 11:14 AM
$NEO 🚀 Why NeoGenomics ($NEO) is Moving Today 1. The "Big Win": RaDaR ST Official Launch After years of legal handcuffs, NeoGenomics officially launched its RaDaR ST assay this week. This is their "Natera-killer"—a high-sensitivity test for cancer recurrence in a market worth over $20 billion. 2. Legal "All-Clear" with Natera The lawsuit you saw regarding InVisionFirst-Lung was just settled. Combined with Natera dropping its major patent appeals in December, NeoGenomics now has zero major legal blockages for the first time in years. They are finally free to sell without fear of court injunctions. 3. Institutional "Relief Rally" The stock took a hit last week on 2026 guidance $NTRA 1️⃣ RaDaR ST Launch: Officially live this week to challenge Natera's dominance in the $20B cancer-tracking market. 2️⃣ Legal Peace: Settled the InVisionFirst suit with $NTRA; patent "war" is essentially over. 3️⃣ Commercial Era: No more courtroom drama—just pure growth and market share capture.
1 · Reply
Latest News on NEO
NeoGenomics Launches RaDaR ST, Expanding Molecular Residual Disease Testing Across Multiple Solid Tumor Types

Feb 25, 2026, 7:05 AM EST - 16 days ago

NeoGenomics Launches RaDaR ST, Expanding Molecular Residual Disease Testing Across Multiple Solid Tumor Types

NeoGenomics to Participate in Upcoming Investor Conferences

Feb 18, 2026, 7:05 AM EST - 23 days ago

NeoGenomics to Participate in Upcoming Investor Conferences

NeoGenomics, Inc. (NEO) Q4 2025 Earnings Call Transcript

Feb 17, 2026, 12:55 PM EST - 24 days ago

NeoGenomics, Inc. (NEO) Q4 2025 Earnings Call Transcript

NeoGenomics Reports Fourth Quarter and Full Year 2025 Results

Feb 17, 2026, 7:05 AM EST - 24 days ago

NeoGenomics Reports Fourth Quarter and Full Year 2025 Results

NeoGenomics Introduces PanTracer Pro to Support Timely, Informed Solid Tumor Therapy Selection

Feb 12, 2026, 7:05 AM EST - 4 weeks ago

NeoGenomics Introduces PanTracer Pro to Support Timely, Informed Solid Tumor Therapy Selection

NeoGenomics to Report Fourth Quarter and Full Year 2025 Financial Results on February 17, 2026

Jan 27, 2026, 7:05 AM EST - 6 weeks ago

NeoGenomics to Report Fourth Quarter and Full Year 2025 Financial Results on February 17, 2026

NeoGenomics: Distribution Moat In Community Oncology

Jan 25, 2026, 5:17 AM EST - 6 weeks ago

NeoGenomics: Distribution Moat In Community Oncology

NeoGenomics, Inc. (NEO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 14, 2026, 12:06 AM EST - 2 months ago

NeoGenomics, Inc. (NEO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

NeoGenomics Announces Preliminary Fourth Quarter and Full-Year 2025 Revenue

Jan 12, 2026, 7:05 AM EST - 2 months ago

NeoGenomics Announces Preliminary Fourth Quarter and Full-Year 2025 Revenue

NeoGenomics to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Jan 5, 2026, 7:05 AM EST - 2 months ago

NeoGenomics to Participate in the 44th Annual J.P. Morgan Healthcare Conference

NeoGenomics Appoints Diagnostics and Lab Services Industry Veteran John P. “Jack” Kenny to its Board of Directors

Dec 30, 2025, 7:05 AM EST - 2 months ago

NeoGenomics Appoints Diagnostics and Lab Services Industry Veteran John P. “Jack” Kenny to its Board of Directors

NeoGenomics Announces that Natera Has Voluntarily Withdrawn its Appeal in Ongoing RaDaR Patent Litigation

Dec 15, 2025, 7:05 AM EST - 3 months ago

NeoGenomics Announces that Natera Has Voluntarily Withdrawn its Appeal in Ongoing RaDaR Patent Litigation

NeoGenomics to Present New ctDNA Research at SABCS 2025

Dec 10, 2025, 7:05 AM EST - 3 months ago

NeoGenomics to Present New ctDNA Research at SABCS 2025

NeoGenomics to Present Real-World Study on Comprehensive Genomic Profiling in Myeloid Malignancies at ASH 2025

Dec 8, 2025, 8:05 AM EST - 3 months ago

NeoGenomics to Present Real-World Study on Comprehensive Genomic Profiling in Myeloid Malignancies at ASH 2025

Neo Performance Materials Inc. (NEO:CA) Q3 2025 Earnings Call Transcript

Nov 14, 2025, 12:41 PM EST - 4 months ago

Neo Performance Materials Inc. (NEO:CA) Q3 2025 Earnings Call Transcript

NeoGenomics to Present RaDaR ST Bridging Study at ISLB 2025, Demonstrating Reliable MRD Detection Across Solid Tumors

Oct 30, 2025, 12:51 PM EDT - 4 months ago

NeoGenomics to Present RaDaR ST Bridging Study at ISLB 2025, Demonstrating Reliable MRD Detection Across Solid Tumors

NeoGenomics, Inc. (NEO) Q3 2025 Earnings Call Transcript

Oct 28, 2025, 3:11 PM EDT - 4 months ago

NeoGenomics, Inc. (NEO) Q3 2025 Earnings Call Transcript

NeoGenomics Reports Third Quarter 2025 Results

Oct 28, 2025, 7:05 AM EDT - 4 months ago

NeoGenomics Reports Third Quarter 2025 Results

NeoGenomics to Highlight RaDaR ST MRD Assay at ESMO Congress 2025

Oct 14, 2025, 7:05 AM EDT - 5 months ago

NeoGenomics to Highlight RaDaR ST MRD Assay at ESMO Congress 2025

NeoGenomics to Report Third Quarter 2025 Financial Results on October 28, 2025

Oct 7, 2025, 7:05 AM EDT - 5 months ago

NeoGenomics to Report Third Quarter 2025 Financial Results on October 28, 2025

NeoGenomics Stock In A Range-Bound Matrix, Weakness Likely Until 2026

Sep 17, 2025, 7:58 AM EDT - 6 months ago

NeoGenomics Stock In A Range-Bound Matrix, Weakness Likely Until 2026

NeoGenomics Gains 'Unexpected' Win As Court Rejects Natera Claims

Aug 29, 2025, 1:04 PM EDT - 7 months ago

NeoGenomics Gains 'Unexpected' Win As Court Rejects Natera Claims

Court Rules for NeoGenomics in Patent Infringement Lawsuit Against Natera

Aug 29, 2025, 7:05 AM EDT - 7 months ago

Court Rules for NeoGenomics in Patent Infringement Lawsuit Against Natera

Neo Performance Materials Inc. (NOPMF) Q2 2025 Earnings Conference Call Transcript

Aug 12, 2025, 6:56 PM EDT - 7 months ago

Neo Performance Materials Inc. (NOPMF) Q2 2025 Earnings Conference Call Transcript

NeoGenomics Launches PanTracer LBx, Expanding Access to Comprehensive Genomic Profiling with Liquid Biopsy

Jul 30, 2025, 7:05 AM EDT - 8 months ago

NeoGenomics Launches PanTracer LBx, Expanding Access to Comprehensive Genomic Profiling with Liquid Biopsy

NeoGenomics, Inc. (NEO) Q2 2025 Earnings Call Transcript

Jul 29, 2025, 4:54 PM EDT - 8 months ago

NeoGenomics, Inc. (NEO) Q2 2025 Earnings Call Transcript

NeoGenomics Reports Second Quarter 2025 Results

Jul 29, 2025, 7:05 AM EDT - 8 months ago

NeoGenomics Reports Second Quarter 2025 Results

NeoGenomics to Report Second Quarter 2025 Financial Results on July 29, 2025

Jul 1, 2025, 7:05 AM EDT - 9 months ago

NeoGenomics to Report Second Quarter 2025 Financial Results on July 29, 2025

NeoGenomics Announces PanTracer Tissue and PanTracer Tissue + HRD Now Available to Support More Informed and Timely Cancer Care

Jun 30, 2025, 7:05 AM EDT - 9 months ago

NeoGenomics Announces PanTracer Tissue and PanTracer Tissue + HRD Now Available to Support More Informed and Timely Cancer Care

NeoGenomics Appoints Dr. Marjorie Green to Board of Directors

Jun 24, 2025, 7:05 AM EDT - 9 months ago

NeoGenomics Appoints Dr. Marjorie Green to Board of Directors

NeoGenomics Debuts PanTracer Family of Genomic Profiling Tests at ASCO 2025

May 28, 2025, 7:10 AM EDT - 10 months ago

NeoGenomics Debuts PanTracer Family of Genomic Profiling Tests at ASCO 2025

NeoGenomics Launches c-MET CDx Assay to Guide Treatment Decisions for Advanced Non-Small Cell Lung Cancer

May 22, 2025, 7:10 AM EDT - 10 months ago

NeoGenomics Launches c-MET CDx Assay to Guide Treatment Decisions for Advanced Non-Small Cell Lung Cancer

NeoGenomics to Participate in Upcoming June Investor Conferences

May 20, 2025, 7:05 AM EDT - 10 months ago

NeoGenomics to Participate in Upcoming June Investor Conferences

NeoGenomics Pays Off 1.25% Convertible Senior Notes

May 1, 2025, 7:05 AM EDT - 11 months ago

NeoGenomics Pays Off 1.25% Convertible Senior Notes

NeoGenomics Q1 Earnings: The Stock Price Drop Is A Gift (Rating Upgrade)

Apr 30, 2025, 9:00 AM EDT - 11 months ago

NeoGenomics Q1 Earnings: The Stock Price Drop Is A Gift (Rating Upgrade)

NeoGenomics, Inc (NEO) Q1 2025 Earnings Call Transcript

Apr 29, 2025, 12:18 PM EDT - 11 months ago

NeoGenomics, Inc (NEO) Q1 2025 Earnings Call Transcript

NeoGenomics and Ultima Genomics collaborate to expand clinical test offerings in Oncology using the UG 100 sequencing platform

Apr 29, 2025, 8:00 AM EDT - 11 months ago

NeoGenomics and Ultima Genomics collaborate to expand clinical test offerings in Oncology using the UG 100 sequencing platform

NeoGenomics Reports First Quarter 2025 Results

Apr 29, 2025, 7:30 AM EDT - 11 months ago

NeoGenomics Reports First Quarter 2025 Results

NeoGenomics to Showcase PanTracer LBx Validation Study at AACR Annual Meeting

Apr 22, 2025, 7:05 AM EDT - 11 months ago

NeoGenomics to Showcase PanTracer LBx Validation Study at AACR Annual Meeting

NeoGenomics to Report First Quarter 2025 Financial Results on April 29, 2025

Apr 8, 2025, 7:05 AM EDT - 1 year ago

NeoGenomics to Report First Quarter 2025 Financial Results on April 29, 2025

NeoGenomics Completes Acquisition of Pathline

Apr 7, 2025, 7:05 AM EDT - 1 year ago

NeoGenomics Completes Acquisition of Pathline

Tony Zook Assumes Role as Chief Executive Officer of NeoGenomics

Apr 1, 2025, 7:05 AM EDT - 1 year ago

Tony Zook Assumes Role as Chief Executive Officer of NeoGenomics

NeoGenomics Expands Oncology Testing Reach in the Northeast with Acquisition of Pathline

Mar 10, 2025, 7:00 AM EDT - 1 year ago

NeoGenomics Expands Oncology Testing Reach in the Northeast with Acquisition of Pathline

NeoGenomics: Decent Fundamentals, But Still Overvalued

Feb 28, 2025, 3:39 AM EST - 1 year ago

NeoGenomics: Decent Fundamentals, But Still Overvalued

carminefox
carminefox Mar. 13 at 9:22 PM
$NEO bag holding this patiently. Hoping for that buy out offer!
0 · Reply
Fabiola_T
Fabiola_T Mar. 13 at 1:08 PM
$NEO lower high set
0 · Reply
DriveForShow
DriveForShow Mar. 12 at 5:04 PM
$NEO Did we finally hit a new bottom?
0 · Reply
Kat_Harington
Kat_Harington Mar. 12 at 2:22 PM
$NEO this thing is DUMPING
0 · Reply
BillionerOfKing
BillionerOfKing Mar. 10 at 8:40 PM
$NEO Current Stock Price: $8.55 Contracts to trade: $9.0 NEO Mar 20 2026 Call Entry: $1.10 Exit: $1.69 ROI: 54% Hold ~29 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
Kat_Harington
Kat_Harington Mar. 9 at 2:16 PM
$NEO haven’t seen a green day in months.
1 · Reply
IN0V8
IN0V8 Mar. 6 at 2:33 PM
$NEO Added at $8.95
0 · Reply
IN0V8
IN0V8 Mar. 2 at 5:49 PM
$NEO added at $9.2
0 · Reply
DriveForShow
DriveForShow Mar. 2 at 3:05 PM
$NEO Figured the 200MA would get tested and it’s just about there. Will it hold $9.23?
0 · Reply
GordoHLYK13
GordoHLYK13 Feb. 27 at 11:14 AM
$NEO 🚀 Why NeoGenomics ($NEO) is Moving Today 1. The "Big Win": RaDaR ST Official Launch After years of legal handcuffs, NeoGenomics officially launched its RaDaR ST assay this week. This is their "Natera-killer"—a high-sensitivity test for cancer recurrence in a market worth over $20 billion. 2. Legal "All-Clear" with Natera The lawsuit you saw regarding InVisionFirst-Lung was just settled. Combined with Natera dropping its major patent appeals in December, NeoGenomics now has zero major legal blockages for the first time in years. They are finally free to sell without fear of court injunctions. 3. Institutional "Relief Rally" The stock took a hit last week on 2026 guidance $NTRA 1️⃣ RaDaR ST Launch: Officially live this week to challenge Natera's dominance in the $20B cancer-tracking market. 2️⃣ Legal Peace: Settled the InVisionFirst suit with $NTRA; patent "war" is essentially over. 3️⃣ Commercial Era: No more courtroom drama—just pure growth and market share capture.
1 · Reply
StockNews_Live
StockNews_Live Feb. 25 at 12:05 PM
$NEO NeoGenomics, Inc. announced the launch of RaDaR ST, its circulating tumor DNA (ctDNA) assay for detecting molecular residual disease (MRD). The assay is approved by Medicare for initial launch indicat…
0 · Reply
Kat_Harington
Kat_Harington Feb. 24 at 8:05 PM
$NEO looking good
0 · Reply
erevnon
erevnon Feb. 24 at 5:41 PM
Piper Sandler maintains NeoGenomics $NEO at Overweight and raises the price target from $12 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
GordoHLYK13
GordoHLYK13 Feb. 21 at 7:07 PM
$NEO $HLYK 2026 Together We Fly https://youtu.be/ztJVbDCifO8?si=1jToNIeu3ri5AA4u
0 · Reply
TaurusBull76
TaurusBull76 Feb. 21 at 2:02 PM
$NEO wow Neo is trending. Interesting.
0 · Reply
GordoHLYK13
GordoHLYK13 Feb. 21 at 1:27 PM
$HLYK HealthLynked (HLYK): Top 6 Catalysts 1. Nasdaq S-1 Filed: Official application for uplisting is active (targeting $4.00–$6.00 range). 2. Nasdaq Debut: Moving from OTC to the "Big Board" opens the door to institutional and retail millions. 3. Insider Confidence: Dr. Dent consolidated $5.7M in debt into a note convertible at $4.25 per share. 4. Payer Pilot: New partnership with PBACO to launch an AI pilot program with UnitedHealthcare. 5. ARi AI Rollout: "National Initiative" launched to integrate the AI assistant with pharma and research giants. 6. Low Float Physics: Only 1.9M shares available; any major news could trigger a "vertical" price squeeze. $NEO
0 · Reply
GordoHLYK13
GordoHLYK13 Feb. 21 at 1:26 PM
$NEO NeoGenomics (NEO): Top 7 Catalysts 1. RaDaR ST Launch: Full U.S. clinical rollout of the "next-gen" cancer test is starting this month (Feb 2026). 2. Lee Health Lab: NEO’s partnership anchored in Lee Health’s new $150M molecular lab expansion. 3. The "Beat & Raise": Q1 earnings (May 2026) likely to smash the "conservative" 2026 guidance. 4. NGS Growth: Revenue for high-profit sequencing is surging at 23% year-over-year. 5. Sales Force Blitz: Expanding to 165 oncology specialists this year to drive massive test volume. 6. Reimbursement Win: MolDx/Medicare pricing for new liquid biopsies is locked in for 2026. 7. Buyout Potential: Dominant Florida footprint makes NEO a prime acquisition target for Quest or LabCorp. $HLYK
0 · Reply
GordoHLYK13
GordoHLYK13 Feb. 21 at 12:55 PM
$HLYK Nasdaq S-1 Filed! Dr. Dent Betting Big! The transformation is real. Dr. Dent (founder of $NEO repeating the playbook. 🩺 The News: HealthLynked just filed its S-1 for Nasdaq uplisting with a target range of $4.00–$6.00. The TCOB Checklist: • Founder Confidence: Dr. Dent just consolidated $5.7M in debt into a note convertible at $4.25. He isn't just the CEO; he's the biggest bull. • Commercial Scalability: ARI AI platform is moving into payer/employer channels (high-margin recurring revenue). • Nasdaq Ready: Cleanup of governance and reporting is done. • Local Synergy: Strategic positioning with Southwest FL medical heavyweights (Millennium, Lee Health, NCH).
0 · Reply
GordoHLYK13
GordoHLYK13 Feb. 21 at 12:54 PM
$NEO While Others Panic! Don't let the post-earnings shakeout fool you. 📊 Dig Deep: NEO just beat Q4 Rev & EPS, hitting its 10th straight quarter of positive Adj. EBITDA. Volume spike at $9.89 + RSI at 26 = classic "capitulation" bottom. Why I’m Bullish: • Institutional Support: Zacks #2 (Buy) upgrade just hit. • Insiders are IN: COO Warren Stone’s recent Form 4 shows he’s holding 120k+ shares and huge options at $13-$19. He only sold a fraction for taxes. • Local Moat: Deeply integrated with Lee Health's new $150M lab expansion and NCH oncology. • RaDaR ST: Full clinical launch this month. The "dishes are done." Accumulating here. 🚀 #Oncology #FortMyers #Value Watch out $NTRA $HLYK CEO Dent $NEO founder
0 · Reply
EarningsCentral
EarningsCentral Feb. 21 at 3:57 AM
$NEO Q4 2025 Earnings | Record Revenue, RaDaR ST Launch & $30B MRD Opportunity https://youtu.be/7ItZ_w_o6eU
0 · Reply
STOCKTRADERCHIA
STOCKTRADERCHIA Feb. 20 at 11:27 PM
$NEO Long triggered at 16:30 at about $6.5s. Bull wedge on a long timeframe too. Clean signal. On the bottom of the first photo, you can see there is a table as well. Up 50% from the tigger event. My custom script available this weekend. You will no longer need to look at how trades unfold, you just need to manage risk. It will automatical look for potential trades.
0 · Reply